Tapestry, Inc. Total Cost of Revenue decreased by 27.7% to $444.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 17.2%, from $378.80M to $444.10M. Over 4 years (FY 2021 to FY 2025), Total Cost of Revenue shows relatively stable performance with a 0.9% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $449.30M | $412.20M | $683.80M | $432.40M | $505.70M | $451.90M | $636.10M | $411.20M | $446.80M | $415.50M | $591.30M | $375.00M | $399.90M | $372.60M | $562.30M | $378.80M | $408.10M | $404.10M | $614.00M | $444.10M |
| QoQ Change | — | -8.3% | +65.9% | -36.8% | +17.0% | -10.6% | +40.8% | -35.4% | +8.7% | -7.0% | +42.3% | -36.6% | +6.6% | -6.8% | +50.9% | -32.6% | +7.7% | -1.0% | +51.9% | -27.7% |
| YoY Change | — | — | — | — | +12.6% | +9.6% | -7.0% | -4.9% | -11.6% | -8.1% | -7.0% | -8.8% | -10.5% | -10.3% | -4.9% | +1.0% | +2.1% | +8.5% | +9.2% | +17.2% |
| Segment | Q1 '26 |
|---|---|
| Coach | $362.00M |
| Kate Spade | $82.10M |
| Stuart Weitzman | $0.00 |
| Total | $444.10M |